Risk Factors of Prolonged QTc Interval in Patients with Drugs-Resistant Tuberculosis
DOI:
https://doi.org/10.36497/jri.v42i1.274Keywords:
regimen, prolonged-QTc, tuberculosis, resitant, electrocardiographyAbstract
Background: Drug-Resistant Tuberculosis (DRTB) is still one of the biggest health problems worldwide. In 2016, WHO published new guidelines for DRTB management using 7 second-line drugs that only required 9-11 months of treatment with a higher success rate. Unfortunately, one of the side effects was the possibility of a prolonged QT-c interval on electrocardiography. However, to date there have been no known factors which increased the risk of QTc prolongation in DRTB patients.
Methods: This was a retrospective cohort study that analyzed the medical records of 50 DRTB patients who underwent treatment from August 2017 to August 2020 at the DRTB Clinic of Adam Malik Hospital Medan. Statistical analysis was performed using logistic regression to determine the factors which increased the risk of QTc prolongation in DRTB patients.
Results: Of the 50 study samples consisting of 40 MDR TB patients, 9 pre-XDR TB patients and 1 XDR TB patient, 14 (28%) subjects were found to have QTc prolongation. There were no correlation between the regimen type (P = 0.51), age (P = 0.40), sex (P = 0.74), nutritional status (P = 0.35) and comorbid diseases (P = 0.31) on the prolongation of QTc interval. Patients receiving clofazimine had a greater percentage (78.6% vs 21.4%) to experience prolonged QTc interval, although not statistically significant (P = 0.41).
Conclusion: Treatment regimen, age, sex, nutritional status and comorbid disease were not associated with prolonged QTc interval in DRTB.
Downloads
References
World Health Organization. Global tuberculosis report 2020. World Health Organization. Geneva; 2020.
Kusmiati T, Mertaniasih NM, Eko Putranto JN, Suprapti B, Soedarsono, Luthfah N, et al. The role of C-Reactive protein as an inflammatory marker to predict prolonged QTc interval in rifampicin-resistant tuberculosis patients: A case-control study. Ann Med Surg. 2021 Oct;70:102899.
Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656–73.
Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3).
Jain NK. WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry? Vol. 38, Lung India. Wolters Kluwer Medknow Publications; 2021. p. 303–6.
Pontali E, Sotgiu G, Tiberi S, D’Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: A systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5):1701462.
Haverkamp W, Kruesmann F, Fritsch A, Veenhuyzen D van, Arvis P. Update on the Cardiac Safety of Moxifloxacin. Curr Drug Saf. 2012;7(2):149.
Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, et al. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. Eur Respir J. 2018;51(3):1702550.
Trinkley KE, Lee Page R, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: Essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–26.
Yoon H-Y, Jo K-W, Nam GB, Shim TS. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis. 2017;21(9):996–1001.
Asfaw MT, Holtzman DL, Kwan GF, Oyewusi LT, Mitnick CD, Seung KJ. Incidence of high grade qtcf prolongation and its management among patients undergoing treatment for drug resistant tuberculosis (dr-tb): case series. African J Infect Dis. 2021;15(2):38–41.
Moodley R, Godec TR. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25(139):29–35.
Pontali E, Raviglione MC, Migliori GB, Akkerman OW, Alffenaar JW, Blanc FX, et al. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035.
Gupta R, Geiter LJ, Hafkin J, Wells CD. Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(10):1261–2.
Cohen K, Maartens G. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Expert Opin Drug Saf. 2019;18(10):875–82.
Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(4):385–91.
Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–72.
Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021;21(7):975–83.
Abdelwahab MT, Court R, Everitt D, Diacon AH, Dawson R, Svensson EM, et al. Effect of clofazimine concentration on qt prolongation in patients treated for tuberculosis. Antimicrob Agents Chemother. 2021;65(7):e0268720.
Zweijpfenning SMH, Van Groningen H, Van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, et al. Clofazimine does not lead to significant QT interval prolongation: A multicentre study. Eur Respir J. 2018;52(5):Clofazimine does not lead to significant QT interv.
Li M, Ramos LG. Drug-Induced QT Prolongation And Torsades de Pointes. Pharm Ther. 2017;42(7):473.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
